骨改良药物在肺癌骨转移中的研究进展
Role of bone-modifying agents in the treatment of bone metastasis in lung cancer
王凯 1王娜 2姜金 1敏思聪 1叶凯山1
作者信息
- 1. 兰州大学第二医院骨科,兰州 730000
- 2. 兰州大学第二医院肿瘤内科,兰州 730000
- 折叠
摘要
目前各指南推荐恶性肿瘤骨转移的内科治疗药物主要为骨改良药物,分为地舒单抗和双膦酸盐类,同时这两类药物也获批适应证为治疗高钙血症、骨质疏松.双膦酸盐类药物临床使用时间长,应用广泛,种类较多,目前分为三代,每代都有不同的代表药物,如一代的依替膦酸二钠、膦酸二钠等,二代的帕米膦酸二钠,三代的唑来膦酸等.肺癌是全球发病率较高的肿瘤,患者就诊时大多已为晚期,其中出现骨转移的患者约占一半,给患者的生活质量带来了巨大的负担,因此一旦明确诊断肺癌骨转移,应尽早使用骨改良药物治疗.本文就骨改良药物在肺癌骨转移中的应用做一综述.
Abstract
Currently,the medical treatment drugs recommended by various guidelines for bone metastasis of malignant tumors are mainly bone-modifying agent,which are divided into desuzumab and bisphosphonate drugs,and these two kinds of drugs are also approved to be used in the treatment of hypercalcemia and osteoporosis.Bisphosphonate drugs have been used in clinic for a long time,with wide applicationed and many varieties.At present,they are divided into three generations,and each generation has different representative drugs,such as the first generation of etidronate chlorophosphonate,the second generation of pamidronate disodium,the third generation of zoledronic acid and so on.Lung cancer is a tumor with a high incidence globally.Most patients are in the advanced stage when they see a doctor,and about half of them show bone metastasis,a huge burden to patients quality of life.Therefore,once the bone metastasis of lung cancer is clearly diagnosed,bone-modifying agent should be used as soon as possible.This article reviewed the application of bone-improving drugs for bone metastasis in lung cancer.
关键词
骨改良药物/肺癌/骨转移Key words
bone-modifying agent/lung cancer/bone metastasis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据